IL183415A - Tartrate salt of isofagomine and methods of use - Google Patents

Tartrate salt of isofagomine and methods of use

Info

Publication number
IL183415A
IL183415A IL183415A IL18341507A IL183415A IL 183415 A IL183415 A IL 183415A IL 183415 A IL183415 A IL 183415A IL 18341507 A IL18341507 A IL 18341507A IL 183415 A IL183415 A IL 183415A
Authority
IL
Israel
Prior art keywords
isofagomine
isofagomine tartrate
tartrate
tartaric acid
water
Prior art date
Application number
IL183415A
Other languages
English (en)
Other versions
IL183415A0 (en
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of IL183415A0 publication Critical patent/IL183415A0/en
Publication of IL183415A publication Critical patent/IL183415A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
IL183415A 2006-05-24 2007-05-24 Tartrate salt of isofagomine and methods of use IL183415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US89071907P 2007-02-20 2007-02-20

Publications (2)

Publication Number Publication Date
IL183415A0 IL183415A0 (en) 2007-09-20
IL183415A true IL183415A (en) 2012-03-29

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183415A IL183415A (en) 2006-05-24 2007-05-24 Tartrate salt of isofagomine and methods of use

Country Status (14)

Country Link
US (2) US7501439B2 (enExample)
EP (1) EP1860101B1 (enExample)
JP (1) JP5292605B2 (enExample)
AT (1) ATE504570T1 (enExample)
AU (1) AU2007202359B2 (enExample)
BR (1) BRPI0706114A2 (enExample)
CA (1) CA2590122C (enExample)
DE (1) DE602007013648D1 (enExample)
DK (1) DK1860101T3 (enExample)
IL (1) IL183415A (enExample)
MX (1) MX2007006175A (enExample)
PL (1) PL1860101T3 (enExample)
PT (1) PT1860101E (enExample)
WO (1) WO2007140212A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
WO2008144773A1 (en) 2007-05-22 2008-11-27 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2009314447A1 (en) * 2008-11-14 2010-05-20 Neuraltus Pharmaceuticals, Inc. Compositions and methods for the treatment of altered alpha-synuclein function
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
RU2608520C2 (ru) * 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
LT2490532T (lt) 2009-10-19 2017-03-27 Amicus Therapeutics, Inc. Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013225816B2 (en) 2012-03-02 2017-10-26 Takeda Pharmaceutical Company Limited Compositions and methods for treating Type III Gaucher Disease
ES2924829T3 (es) 2012-03-27 2022-10-11 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
CN111278439A (zh) * 2017-10-26 2020-06-12 夏尔人类遗传性治疗公司 包含葡萄糖脑苷脂酶和异烟肼的调配物
MX2020014082A (es) 2018-06-27 2021-04-13 Proteostasis Therapeutics Inc Compuestos que mejoran la actividad del proteasoma.
JP7551087B2 (ja) 2018-06-27 2024-09-17 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP7642561B2 (ja) * 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Also Published As

Publication number Publication date
US20070281975A1 (en) 2007-12-06
EP1860101B1 (en) 2011-04-06
WO2007140212A2 (en) 2007-12-06
JP5292605B2 (ja) 2013-09-18
AU2007202359B2 (en) 2012-02-16
IL183415A0 (en) 2007-09-20
US7863453B2 (en) 2011-01-04
CA2590122A1 (en) 2007-11-24
BRPI0706114A2 (pt) 2008-11-18
US20090176830A1 (en) 2009-07-09
DE602007013648D1 (de) 2011-05-19
CA2590122C (en) 2015-03-31
MX2007006175A (es) 2009-02-16
US7501439B2 (en) 2009-03-10
PT1860101E (pt) 2011-07-12
ATE504570T1 (de) 2011-04-15
EP1860101A1 (en) 2007-11-28
JP2007314540A (ja) 2007-12-06
DK1860101T3 (da) 2011-07-25
PL1860101T3 (pl) 2011-10-31
WO2007140212A3 (en) 2008-12-24
AU2007202359A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
IL183415A (en) Tartrate salt of isofagomine and methods of use
US20110237538A1 (en) Treatment of lysosomal storage disorders and other proteostatic diseases
JP4767172B2 (ja) ゴーシェ病を治療するための、ヒドロキシピペリジン誘導体
US20100317690A1 (en) Treatment of protein folding disorders
JP5645918B2 (ja) リソソーム蓄積障害の予防および／または治療方法
JP2024054192A (ja) 医薬化合物の結晶形態
WO2010116141A2 (en) Drug combination for the treatment of proteostatic diseases
JP2025061797A (ja) 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法
KR20100017879A (ko) 이소파고민과 이의 유도체를 제조하는 새로운 방법
US9896416B2 (en) Piperidinium quaternary salts
ES2364586T3 (es) Sal tartrato de isofagomina y métodos de uso.
US10519157B2 (en) Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
Li et al. Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of enzyme replacement therapy in Pompe disease
CN114685519A (zh) 一类吡喃并咔唑生物碱衍生物及其治疗阿尔茨海默症的用途
JP7809655B2 (ja) 医薬化合物の結晶形態
WO2011095772A2 (en) Novel iminosugar therapeutics
WO2025219951A1 (en) Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders
WO2011131926A1 (en) Novel iminosugar combinations
Davighi NITROGENATED MONO-, MULTIVALENT AND STIMULI RESPONSIVE GLYCOMIMETICS FOR BIOMEDICAL APPLICATIONS
KR20090100360A (ko) 중추신경계 장애 치료제로서의 피바가빈의 디알킬아미노 알킬 에스테르
Clemente Synthesis of alkylated azasugars and their therapeutic potential against lysosomal storage and neurological disorders: the Gaucher-Parkinson case
WO2024056798A1 (en) Macrocyclic cftr modulators
EP4507682A1 (en) Iduronidase stabilizers and uses thereof
NZ615857B2 (en) Glucosylceramide synthase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed